IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/pharmasgp-gmbh" target="_blank" data-smartkarma-citation="entities:29009:1" rel="noopener">PharmaSGP (1780644D GR)</a> is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter (OTC) and other healthcare products. PharmaSGP has launched an IPO on the Frankfurt Stock Exchange at a price range of €31.50-36.50 per share. The offer, which a purely a secondary raise, will raise gross proceeds of €304.3-352.6 million for the selling shareholders. The book-building process is expected to end on 18 June, with trading expected to commence on 19 June.</p><div class="content-highlight"><p>PharmaSGP is a play on the chemical-free OTC market in Continental Europe which is growing due to the ageing of the population, a trend towards self-medication and the growing demand for natural remedies. Overall, PharmaSGP offers strong fundamentals at an attractive valuation, in our view.</p></div>

PharmaSGP (1780644D GR) is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter (OTC) and other healthcare products. PharmaSGP has launched an IPO on the Frankfurt Stock Exchange at a price range of €31.50-36.50 per share. The offer, which a purely a secondary raise, will raise gross proceeds of €304.3-352.6 million for the selling shareholders. The book-building process is expected to end on 18 June, with trading expected to commence on 19 June.PharmaSGP is a play on the chemical-free OTC market in Continental Europe which is growing due to the ageing of the population, a trend towards self-medication and the growing demand for natural remedies. Overall, PharmaSGP offers strong fundamentals at an attractive valuation, in our view.

PharmaSGP IPO Initiation: Potent Medicine

Germany

PharmaSGP Holding SE operates as a pharmaceutical company. The Company produces and develops non-chemical and over the counter drugs and other healthcare products. PharmaSGP Holding serves customers in Germany

PharmaSGP (PSG GR)

PharmaSGP IPO Initiation: Potent Medicine

PharmaSGP (1780644D GR) is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals...

Arun George